-transparent.png){kind=logo}
Methyl-CCNU (NSC-95441) was administered to patients with malignant melanoma in a split dose schedule. Nausea and vomiting were eliminated as clinical problems during therapy. Response rate to the drug seemed somewhat lower than the average of three previously reported disease-oriented phase II trials, though the difference was not significant statistically. The time course of myelosuppression seemed comparable to that seen with a single dose schedule of administration.
Related Publications
R E Wittes, and
W K Hong, and
L Gatchell, and
I H Krakoff, and
R B Golbey
June 1974,
Clinical pharmacology and therapeutics,
R E Wittes, and
W K Hong, and
L Gatchell, and
I H Krakoff, and
R B Golbey
December 1998,
Medical and pediatric oncology,
R E Wittes, and
W K Hong, and
L Gatchell, and
I H Krakoff, and
R B Golbey
January 1980,
Cancer treatment reports,
R E Wittes, and
W K Hong, and
L Gatchell, and
I H Krakoff, and
R B Golbey
April 1984,
American journal of clinical oncology,
R E Wittes, and
W K Hong, and
L Gatchell, and
I H Krakoff, and
R B Golbey
December 1981,
The American journal of medicine,
R E Wittes, and
W K Hong, and
L Gatchell, and
I H Krakoff, and
R B Golbey
August 1977,
Cancer treatment reports,
R E Wittes, and
W K Hong, and
L Gatchell, and
I H Krakoff, and
R B Golbey
December 1977,
Cancer treatment reports,
R E Wittes, and
W K Hong, and
L Gatchell, and
I H Krakoff, and
R B Golbey
June 1971,
Cancer chemotherapy reports,
R E Wittes, and
W K Hong, and
L Gatchell, and
I H Krakoff, and
R B Golbey
June 1976,
Clinical pharmacology and therapeutics,
R E Wittes, and
W K Hong, and
L Gatchell, and
I H Krakoff, and
R B Golbey
September 1977,
Cancer,
